N@N

Novo Nordisk A/S: Novo Nordisk A/S: Total voting rights

^{Published on 2009-06-30 01:32:56, Last Modified on 2009-06-30 01:33:30 - Market Wire}
 

BAGSVAERD, DENMARK--(Marketwire - June 30, 2009) - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2009.

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred.

Referring to Company Announcement no 35/2009 dated 22 June 2009, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk as per 30 June 2009.

 +-------------------------------------------------------------------+ | | Number of shares | Nominal value | Number of votes | | | (nominal value | (DKK) | | | | DKK 1) | | | |----------+----------------------+---------------+-----------------| | | | | | | A shares | | 107,487,200 | 107,487,200,000 | | | 107,487,200 | | | |----------+----------------------+---------------+-----------------| | | | | | | B shares | | 512,512,800 | | | | 512,512,800 | | 51,251,280,000 | +-------------------------------------------------------------------+ 

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

 For further information please contact: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 [ ekh@novonordisk.com ][ mlau@novonordisk.com ] Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 [ krop@novonordisk.com ] In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 [ secl@novonordisk.com ][ hrmm@novonordisk.com ]

Company Announcement 38 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.